BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

Increased α-synuclein expression is implicated both in hereditary and sporadic Parkinson's disease. Proteomic analysis has identified a series of post-translational modifications in inclusions.

Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for ...

Enter SynPull, a new synaptosome imaging method developed by David Klenerman, John Danial, and colleagues at the University of Cambridge, England. SynPull combines single-molecule pull-down of ...

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the ...

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

Parkinson’s disease is a brain disorder that affects movement, making everyday tasks difficult for nearly one million people ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Conductor Daniel Barenboim says he has been diagnosed with Parkinson's disease. The 82-year-old issued a statement Thursday ...